A Randomized Controlled Trial Comparing Continuous Sciatic Nerve Block to Single Shot Sciatic Nerve Block
Overview
- Phase
- Phase 4
- Intervention
- Bupivacaine
- Conditions
- Fracture of Foot
- Sponsor
- Northwestern University
- Enrollment
- 17
- Locations
- 1
- Primary Endpoint
- Temporary Neurologic Symptoms Between Groups
- Status
- Terminated
- Last Updated
- 9 years ago
Overview
Brief Summary
The purpose of this study is to compare the incidence of postoperative symptoms of neurologic injury after a single shot infragluteal-parabiceps sciatic nerve block versus a continuous infragluteal-parabiceps sciatic nerve catheter.
Detailed Description
There are a limited number of prospective studies in the literature examining the risk of neurologic injury and symptoms after sciatic nerve blocks. The incidence of transient neurological symptoms after a continuous catheter is not well reported.
Investigators
Antoun Nader
Professor of Anesthesiology
Northwestern University
Eligibility Criteria
Inclusion Criteria
- •all patients ( ≥18 and ≤ 80) who are scheduled to undergo elective scheduled foot surgery and agreed to receive a sciatic nerve catheter as a part of their postoperative pain management. this study.
Exclusion Criteria
- •history of hemostatic abnormalities
- •chronic pain syndrome
- •a foot deformity restricting normal foot movement
- •severe liver or renal disease
- •a preexisting neurologic disorder
- •patient refusal to participate
- •the presence of language barrier that prohibits proper communication with patient.
Arms & Interventions
Single Shot Sciatic Nerve Block
Single shot sciatic nerve blocks will be performed by resident trainees supervised by faculty. Bupivacaine 0.625% with epinephrine 1:300,000 will be injected incrementally in 3-ml aliquots to a total volume of 0.4 ml/kg (minimum, 20 ml; maximum, 35 ml).
Intervention: Bupivacaine
Continuous Sciatic Nerve Block
Continuous sciatic nerve block catheters will be performed using an insulated needle connected to the negative lead of a constant current nerve stimulator. The catheter will be advanced under ultrasound guidance. A test dose of 1.5% lidocaine with epinephrine will be injected to confirm catheter placement. All subjects will receive a portable pump that will infuse 0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr. The subjects will follow standard protocol discharge instructions in regards to removing the catheter themselves.
Intervention: Ropivacaine
Outcomes
Primary Outcomes
Temporary Neurologic Symptoms Between Groups
Time Frame: 1 month
Temporary neurologic symptoms between groups; muscle weakness of either foot dorsiflexion and plantar flexion
Secondary Outcomes
- Pain Control(72 hrs)
- Participant Satisfaction With Anesthesia(24 hours)